Research groups
Colleges
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Golubic R. et al, (2024), Diabet Med
-
New Approaches to the Treatment of Hypercortisolism.
Pofi R. et al, (2024), Annu Rev Med
-
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency.
Dong J. and Tomlinson JW., (2024), Lancet Diabetes Endocrinol
-
Prospective cohort for early detection of liver cancer (Pearl): a study protocol.
Khanna K. et al, (2024), BMJ Open, 14
-
Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans
Westcott F. et al, (2024), European Journal of Endocrinology (EJE)